Evidence map›Paper›PMID 25589511›Full record

Trial reportAnnals of the rheumatic diseases2016

Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib.

Marc C Hochberg, Johanne Martel-Pelletier, Jordi Monfort, Ingrid Möller, Juan Ramón Castillo, Nigel Arden, Francis Berenbaum, Francisco J Blanco, Philip G Conaghan, Gema Doménech and 7 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IVMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of the rheumatic diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01425853 (Non-Inferiority Clinical Trial On The Efficacy And Safety Of Chondroitin Sulfate And Glucosamine Hydrochloride In Combination Versus Celecoxib In Patients With Knee Osteoarthritis), which is not on this map. Cited by 98 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 8 pooled it
25.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01425853 phase4completednot on this map

Non-Inferiority Clinical Trial On The Efficacy And Safety Of Chondroitin Sulfate And Glucosamine Hydrochloride In Combination Versus Celecoxib In Patients With Knee Osteoarthritis

TypeinterventionalSponsorBioibericaRan2011 to 2013Enrolled606ConditionsKnee OsteoarthritisArmsChondroitin/Glucosamine (Droglican), Celecoxib
3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 8 syntheses or guidelines pooled it, 275 citations in OpenAlex.

  1. Pooled it
  2. Low dose NSAIDs and sysadoas in the management of knee osteoarthritis.Aging clinical and experimental research · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Review
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 13 institutions in 8 countries.

Marc C HochbergUniversity of Maryland School of Medicine, Baltimore, Maryland, USA.
Johanne Martel-PelletierOsteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada.
Jordi MonfortServei de Reumatologia, Hospital del Mar, Barcelona, Spain IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
Ingrid MöllerInstituto Poal de Reumatología, Barcelona, Spain.
Juan Ramón CastilloClinical Pharmacology Unit, Virgen del Rocío University Hospital, Seville, Spain.
Nigel ArdenOxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK Arthritis Research UK, Centre for Sports, Exercise and Osteoarthritis, University of Oxford, Nuffield Orthopaedic Centre, Oxford, UK.
Francis BerenbaumDepartment of Rheumatology, Sorbonne University, INSERM UMR S938, UPMC, University of Paris 06, DHU i2B, Assistance Publique-Hôpitaux de Paris, Saint-Antoine Hospital, Paris, France.
Francisco J BlancoINIBIC-Complejo Hospitalario Universitario A Coruña, A Coruña, Spain.
Philip G ConaghanLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & National Institute for Health Research Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK.
Gema DoménechAsociación Hipótesis Alternativa (H1), Biostatistics Unit, Faculty of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
Yves HenrotinBone and Cartilage Research Unit, Arthropôle Liège, University of Liège, Institute of Pathology, CHU Sart-Tilman, Liège, Belgium Physical Therapy and Rehabilitation Department, Princess Paola Hospital, Marche-en-Famenne, Belgium.
Thomas PapInstitute of Experimental Musculoskeletal Medicine, University Hospital Münster, Münster, Germany.
Pascal RichetteUniversité Paris Diderot, UFR Médicale; Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie, Paris, France INSERM 1132, Université Paris-Diderot, Hôpital Lariboisière, Paris, France.
Allen SawitzkeUniversity of Utah School of Medicine, Salt Lake City, Utah, USA.
Patrick du SouichDepartment of Pharmacology, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.
Jean-Pierre PelletierOsteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada.
MOVES Investigation Group
Université de Montréal · CAInserm · FRComplexo Hospitalario Universitario A Coruña · ESFundacion Instituto de Reumatologia Fernando Chalem · COHospital Del Mar · ESHospital Universitario Virgen del Rocío · ESNuffield Orthopaedic Centre · GBUniversitat Autònoma de Barcelona · ESUniversity Hospital Münster · DEUniversity of Leeds · GBUniversity of Liège · BEUniversity of Maryland, Baltimore · USUniversity of Utah · US

Funding

Medical Research Council MR/L01629X/1
6 · The paper itself

Abstract

objectivesTo compare the efficacy and safety of chondroitin sulfate plus glucosamine hydrochloride (CS+GH) versus celecoxib in patients with knee osteoarthritis and severe pain.

methodsDouble-blind Multicentre Osteoarthritis interVEntion trial with SYSADOA (MOVES) conducted in France, Germany, Poland and Spain evaluating treatment with CS+GH versus celecoxib in 606 patients with Kellgren and Lawrence grades 2-3 knee osteoarthritis and moderate-to-severe pain (Western Ontario and McMaster osteoarthritis index (WOMAC) score ≥301; 0-500 scale). Patients were randomised to receive 400 mg CS plus 500 mg GH three times a day or 200 mg celecoxib every day for 6 months. The primary outcome was the mean decrease in WOMAC pain from baseline to 6 months. Secondary outcomes included WOMAC function and stiffness, visual analogue scale for pain, presence of joint swelling/effusion, rescue medication consumption, Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) criteria and EuroQoL-5D.

resultsThe adjusted mean change (95% CI) in WOMAC pain was -185.7 (-200.3 to -171.1) (50.1% decrease) with CS+GH and -186.8 (-201.7 to -171.9) (50.2% decrease) with celecoxib, meeting the non-inferiority margin of -40: -1.11 (-22.0 to 19.8; p=0.92). All sensitivity analyses were consistent with that result. At 6 months, 79.7% of patients in the combination group and 79.2% in the celecoxib group fulfilled OMERACT-OARSI criteria. Both groups elicited a reduction >50% in the presence of joint swelling; a similar reduction was seen for effusion. No differences were observed for the other secondary outcomes. Adverse events were low and similarly distributed between groups.

conclusionsCS+GH has comparable efficacy to celecoxib in reducing pain, stiffness, functional limitation and joint swelling/effusion after 6 months in patients with painful knee osteoarthritis, with a good safety profile. TRIAL REGISTRATION NUMBER: NCT01425853.

Indexed as

AgedCelecoxibChondroitin SulfatesCyclooxygenase 2 InhibitorsDouble-Blind MethodDrug CombinationsEdemaFemaleGlucosamineHumansMaleMiddle AgedMusculoskeletal PainOsteoarthritis, KneePain MeasurementQuality of LifeCelecoxibChondroitin SulfatesCyclooxygenase 2 InhibitorsDrug CombinationsGlucosamineAnalgesicsNSAIDsOsteoarthritis

Identifiers

PMID25589511
PMCPMC4717399
OpenAlexW2156661254

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.